Pathophysiology of chronic kidney disease-mineral and bone disorder

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 544-549

  Mac Way, Fabrice ^a,b,c   Lessard, Myriam ^a,b,d   Lafage Proust, Marie Hélène ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c LAVAL UNIVERSITY   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Bone biopsy; Bone turnover; FGF23; Osteomalacia; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; SCLEROSTIN;

ACIDOSIS; BONE DISEASE; BONE MINERALIZATION; BONE TURNOVER; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HUMAN; HYPOCALCEMIA; IATROGENIC DISEASE; MINERAL METABOLISM; NONHUMAN; NUTRITIONAL DEFICIENCY; OSTEITIS FIBROSA; OSTEOCYTE; OSTEOLYSIS; OSTEOMALACIA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RENAL OSTEODYSTROPHY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SHORT SURVEY;

BONE DENSITY; BONE DISEASES; CALCIUM; COMORBIDITY; FIBROBLAST GROWTH FACTORS; HUMANS; PARATHYROID HORMONE; PHOSPHORUS; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84870682576     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.09.014     Document Type: Short Survey

References (30)

1. Moe S., Drüeke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
2. Lavi-Moshayoff V., Wasserman G., Meir T., et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
3. Saji F., Shigematsu T., Sakaguchi T., et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010, 299:F1212-F1217.
4. Shigematsu T., Kazama J.J., Yamashita T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004, 44:250-256.
5. Lafage-Proust M.H. Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients?. Kidney Int 2010, 77:390-392.
6. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 1:4003-4008.
7. Shimada T., Hasegawa H., Yamazaki Y., et al. Yamashita T.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
8. Silver J., Naveh-Many T. Phosphate and the parathyroid. Kidney Int 2009, 75:898-905.
9. Tomida K., Hamano T., Mikami S., et al. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 2009, 44:678-683.
10. Ghazali A., Fardellone P., Pruna A., et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol. Kidney Int 1999, 55:2169-2177.
11. Gogusev J., Duchambon P., Hory B., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997, 5:328-336.
12. Brown A.J., Dusso A., Lopez-Hilker S., et al. 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989, 3:19-23.
13. Komaba H., Goto S., Fujii H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010, 77:232-238.
14. Souberbielle J.C., Boutten A., Carlier M.C., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006, 70:345-350.
15. Martin A., Liu S., David V., et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011, 25:2551-2562.
16. Pereira R.C., Juppner H., Azucena-Serrano C.E., et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
17. Kramer I., Halleux C., Keller H., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30:3071-3085.
18. Rhee Y., Bivi N., Farrow E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:636-643.
19. Sabbagh Y., Graciolli F.G., O'Brien S., et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27:1757. doi:10.1002/jbmr.1630.
20. Thambiah S., Roplekar R., Manghat P., et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012, 90:473-480.
21. Cejka D., Herberth J., Branscum A.J., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011, 6:877-882.
22. Shanahan C.M., Crouthamel M.H., Kapustin A., et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109:697-711.
23. Picton M.L., Moore P.R., Mawer E.B., et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000, 58:1440-1449.
24. Mathew S., Davies M., Lund R., et al. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006, 36:43-50.
25. London G.M., Marty C., Marchais S.J., et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004, 15:1943-1951.
26. Karohl C., de Paiva Paschoal J., de Castro M.C., et al. Effects of bone remodelling on calcium mass transfer during haemodialysis. Nephrol Dial Transplant 2010, 25:1244-1251.
27. Atkins G.J., Rowe P.S., Lim H.P., et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 2011, 26:1425-1436.
28. Lafage M.H., Combe C., Fournier A., et al. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992, 42:1217-1225.
29. Jadoul M., Albert J.M., Akiba T., et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006, 70:1358-1366.
30. Bacchetta J., Boutroy S., Guebre-Egziabher F., et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009, 24:3120-3125.